Compile Data Set for Download or QSAR
maximum 50k data
Found 1876 with Last Name = 'raboisson' and Initial = 'p'
TargetGenome polyprotein(Hepatitis C virus)
Janssen Ireland

US Patent
LigandPNGBDBM123410(US8741926, 82 | US8754106, 82 | US8754106, 91)
Affinity DataKi:  0.0500nMAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGenome polyprotein(Hepatitis C virus)
Janssen Ireland

US Patent
LigandPNGBDBM123407(US8741926, 91)
Affinity DataKi:  0.0500nM ΔG°:  -59.8kJ/molepH: 7.5 T: 2°CAssay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Janssen Ireland

US Patent
LigandPNGBDBM236565(US9365582, 5)
Affinity DataKi:  0.100nMpH: 7.5Assay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGenome polyprotein(Hepatitis C virus)
Janssen Ireland

US Patent
LigandPNGBDBM124106(US8754106, 56)
Affinity DataKi:  0.100nMAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGenome polyprotein(Hepatitis C virus)
Janssen Ireland

US Patent
LigandPNGBDBM123411(US8741926, 56)
Affinity DataKi:  0.100nM ΔG°:  -58.0kJ/molepH: 7.5 T: 2°CAssay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Janssen Ireland

US Patent
LigandPNGBDBM236563(US9365582, 3)
Affinity DataKi:  0.100nMpH: 7.5Assay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGenome polyprotein(Hepatitis C virus)
Janssen Ireland

US Patent
LigandPNGBDBM123415(US8741926, 95 | US8754106, 95)
Affinity DataKi:  0.100nM ΔG°:  -58.0kJ/molepH: 7.5 T: 2°CAssay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGenome polyprotein(Hepatitis C virus)
Janssen Ireland

US Patent
LigandPNGBDBM123415(US8741926, 95 | US8754106, 95)
Affinity DataKi:  0.100nMAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Janssen Ireland

US Patent
LigandPNGBDBM236566(US9365582, 7)
Affinity DataKi:  0.100nMpH: 7.5Assay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGenome polyprotein(Hepatitis C virus)
Janssen Ireland

US Patent
LigandPNGBDBM123413(US8741926, 94 | US8754106, 94)
Affinity DataKi:  0.100nM ΔG°:  -58.0kJ/molepH: 7.5 T: 2°CAssay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGenome polyprotein(Hepatitis C virus)
Janssen Ireland

US Patent
LigandPNGBDBM123413(US8741926, 94 | US8754106, 94)
Affinity DataKi:  0.100nMAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Janssen Ireland

US Patent
LigandPNGBDBM236571(US9365582, 13)
Affinity DataKi:  0.100nMpH: 7.5Assay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Janssen Ireland

US Patent
LigandPNGBDBM236573(US9365582, 15)
Affinity DataKi:  0.200nMpH: 7.5Assay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGenome polyprotein(Hepatitis C virus)
Janssen Ireland

US Patent
LigandPNGBDBM123414(US8741926, 48 | US8754106, 48)
Affinity DataKi:  0.25nMAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGenome polyprotein(Hepatitis C virus)
Janssen Ireland

US Patent
LigandPNGBDBM123414(US8741926, 48 | US8754106, 48)
Affinity DataKi:  0.25nM ΔG°:  -55.7kJ/molepH: 7.5 T: 2°CAssay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGenome polyprotein(Hepatitis C virus)
Janssen Ireland

US Patent
LigandPNGBDBM123412(US8741926, 57 | US8754106, 57)
Affinity DataKi:  0.300nM ΔG°:  -55.3kJ/molepH: 7.5 T: 2°CAssay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGenome polyprotein(Hepatitis C virus)
Janssen Ireland

US Patent
LigandPNGBDBM123412(US8741926, 57 | US8754106, 57)
Affinity DataKi:  0.300nMAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGenome polyprotein(Hepatitis C virus)
Janssen Ireland

US Patent
LigandPNGBDBM50336504((2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl...)
Affinity DataKi:  0.5nM ΔG°:  -54.0kJ/molepH: 7.5 T: 2°CAssay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
TargetGenome polyprotein(Hepatitis C virus)
Janssen Ireland

US Patent
LigandPNGBDBM50336504((2R,3aR,10Z,11aS,12aR,14aR)-N-(cyclopropylsulfonyl...)
Affinity DataKi:  0.5nMAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Janssen Ireland

US Patent
LigandPNGBDBM236569(US9365582, 11)
Affinity DataKi:  0.5nMpH: 7.5Assay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Janssen Ireland

US Patent
LigandPNGBDBM236567(US9365582, 9)
Affinity DataKi:  0.800nMpH: 7.5Assay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGenome polyprotein(Hepatitis C virus)
Janssen Ireland

US Patent
LigandPNGBDBM123408(US8741926, 55)
Affinity DataKi:  5nM ΔG°:  -48.2kJ/molepH: 7.5 T: 2°CAssay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGenome polyprotein(Hepatitis C virus)
Janssen Ireland

US Patent
LigandPNGBDBM124105(US8754106, 55)
Affinity DataKi:  5nMAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Janssen Ireland

US Patent
LigandPNGBDBM236568(US9365582, 10)
Affinity DataKi:  7.70nMpH: 7.5Assay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGenome polyprotein(Hepatitis C virus)
Janssen Ireland

US Patent
LigandPNGBDBM123410(US8741926, 82 | US8754106, 82 | US8754106, 91)
Affinity DataKi:  9.40nMAssay Description:The aim of this in vitro assay was to measure the inhibition of HCV NS3/4A protease complexes by the compounds of the present invention. This assay p...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGenome polyprotein(Hepatitis C virus)
Janssen Ireland

US Patent
LigandPNGBDBM123410(US8741926, 82 | US8754106, 82 | US8754106, 91)
Affinity DataKi:  9.40nM ΔG°:  -46.6kJ/molepH: 7.5 T: 2°CAssay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Janssen Ireland

US Patent
LigandPNGBDBM236570(US9365582, 12)
Affinity DataKi:  17nMpH: 7.5Assay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMetabotropic glutamate receptor 5(Homo sapiens (Human))
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50395922(CHEMBL2164552)
Affinity DataKi:  17.9nMAssay Description:Displacement of [3H]AZD9272 from human mGluR5 expressed in HEK293 cell membranes expressing GLAST after 1 hr by scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetMetabotropic glutamate receptor 5(Homo sapiens (Human))
Astrazeneca

Curated by ChEMBL
LigandPNGBDBM50395922(CHEMBL2164552)
Affinity DataKi:  28nMAssay Description:Displacement of [3H]MPEP from human mGluR5 expressed in HEK293 cell membranes expressing GLAST after 1 hr by scintillation counterMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Janssen Ireland

US Patent
LigandPNGBDBM236562(US9365582, 2)
Affinity DataKi:  37nMpH: 7.5Assay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Janssen Ireland

US Patent
LigandPNGBDBM236564(US9365582, 4)
Affinity DataKi:  46nMpH: 7.5Assay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGenome polyprotein [1027-1711](Hepatitis C virus genotype 1a (strain H77) (HCV))
Janssen Ireland

US Patent
LigandPNGBDBM236572(US9365582, 14)
Affinity DataKi:  58nMpH: 7.5Assay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetRNA-directed RNA polymerase(Hepatitis C virus)
Janssen Infectious Diseases - Diagnostics

Curated by ChEMBL
LigandPNGBDBM50495952(CHEMBL3121489)
Affinity DataKi:  130nMAssay Description:Inhibition of HCV RNA polymeraseMore data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails ArticlePubMed
TargetGenome polyprotein(Hepatitis C virus)
Janssen Ireland

US Patent
LigandPNGBDBM123409(US8741926, 81)
Affinity DataKi:  1.00E+3nM ΔG°:  -34.8kJ/molepH: 7.5 T: 2°CAssay Description:The inhibition of full-length hepatitis C NS3 protease enzyme was measured essentially as described in Poliakov, 2002 Prot Expression & Purification ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Upr 421 Du Cnrs

Curated by ChEMBL
LigandPNGBDBM50034908((2R,3S)-3-((R)-6-Amino-purin-9-yl)-nonan-2-ol | (2...)
Affinity DataKi:  2.80E+3nMAssay Description:Inhibition of Phosphodiesterase 2More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Upr 421 Du Cnrs

Curated by ChEMBL
LigandPNGBDBM50058210(CHEMBL445098 | [9-(2-Fluoro-benzyl)-9H-purin-6-yl]...)
Affinity DataKi:  6.50E+3nMAssay Description:Inhibition of Phosphodiesterase 5More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Upr 421 Du Cnrs

Curated by ChEMBL
LigandPNGBDBM50058210(CHEMBL445098 | [9-(2-Fluoro-benzyl)-9H-purin-6-yl]...)
Affinity DataKi:  1.22E+5nMAssay Description:Inhibition of Phosphodiesterase 2More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Upr 421 Du Cnrs

Curated by ChEMBL
LigandPNGBDBM50034908((2R,3S)-3-((R)-6-Amino-purin-9-yl)-nonan-2-ol | (2...)
Affinity DataKi: >2.00E+5nMAssay Description:Inhibition of Phosphodiesterase 5More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Upr 421 Du Cnrs

Curated by ChEMBL
LigandPNGBDBM14361((R,S)-Rolipram | 4-(3-cyclopentyloxy-4-methoxy-phe...)
Affinity DataKi: >2.00E+5nMAssay Description:Inhibition of Phosphodiesterase 5More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Upr 421 Du Cnrs

Curated by ChEMBL
LigandPNGBDBM14361((R,S)-Rolipram | 4-(3-cyclopentyloxy-4-methoxy-phe...)
Affinity DataKi: >2.00E+5nMAssay Description:Inhibition of Phosphodiesterase 2More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetHemagglutinin()
Janssen Sciences Ireland Uc

US Patent
LigandPNGBDBM611021(US10626108, Compound 15)
Affinity DataIC50:  0.200nMAssay Description:The in vitro antiviral activity of the compounds was determined using a cell-based antiviral assay. In this assay, the cytopathic effect (CPE) in Mad...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-5(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50166693(3-Pyridin-3-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]na...)
Affinity DataIC50:  0.210nMAssay Description:Binding affinity to Integrin alpha-v-beta-5 receptor by ELISA assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50166693(3-Pyridin-3-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]na...)
Affinity DataIC50:  0.25nMAssay Description:Binding affinity to Integrin alpha-v-beta-3 receptor by ELISA assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50166678(3-Benzo[1,3]dioxol-5-yl-3-{5-[2-(5,6,7,8-tetrahydr...)
Affinity DataIC50:  0.380nMAssay Description:Binding affinity to Integrin alpha-v-beta-3 receptor by ELISA assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPolymerase basic protein 2(Influenza A virus (strain A/WS/1933 H1N1))
Janssen Biopharma

US Patent
LigandPNGBDBM552303(US11312727, Compound 123A)
Affinity DataIC50:  0.400nMAssay Description:EN PA FRET inhibition assay was performed using a 19 nucleotide synthetic oligoribonucleotide substrate: 5′-FAM-AUUUUGUUUUUAAUAUUUC-BHQ-3′...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50201116(3-(3-pyridyl)-3-[4-[2-(5,6,7,8-tetrahydro[1,8]naph...)
Affinity DataIC50:  0.5nMAssay Description:Binding affinity to Integrin alpha-v-beta-3 receptor by ELISA assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-5(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50166678(3-Benzo[1,3]dioxol-5-yl-3-{5-[2-(5,6,7,8-tetrahydr...)
Affinity DataIC50:  0.5nMAssay Description:Binding affinity to Integrin alpha-v-beta-5 receptor by ELISA assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-5(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50166691(3-Phenyl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyr...)
Affinity DataIC50:  0.680nMAssay Description:Binding affinity to Integrin alpha-v-beta-5 receptor by ELISA assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50235980(2-((2S,5R,8S,11S)-5-benzyl-11-(3-guanidinopropyl)-...)
Affinity DataIC50:  0.860nMAssay Description:Binding affinity to Integrin alpha-v-beta-3 receptor by ELISA assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrin alpha-V/beta-5(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development

Curated by ChEMBL
LigandPNGBDBM50201116(3-(3-pyridyl)-3-[4-[2-(5,6,7,8-tetrahydro[1,8]naph...)
Affinity DataIC50:  0.960nMAssay Description:Binding affinity to Integrin alpha-v-beta-5 receptor by ELISA assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 1876 total ) | Next | Last >>
Jump to: